Most Read Articles
Rachel Soon, 03 Apr 2019

The Malaysian Community Pharmacy Guild (MCPG) has submitted a seven-point proposal for comprehensively including community pharmacists (CPs) in the national healthcare system.

14 May 2019
At the recent GLYCEMIC GUARDIANS™ dinner symposium, three eminent speakers spoke on theindispensable role of medical nutrition therapy (MNT) in improving outcomes for patients with type2 diabetes (T2D).
Rachel Soon, 24 Apr 2019

With recent recalls of losartan-containing products contaminated by potentially carcinogenic nitrosamines, MIMS speaks to the Malaysian National Pharmaceutical Regulatory Agency (NPRA) for more details.

Rachel Soon, 12 Dec 2018

MIMS Pharmacist speaks to Cpt. Manvikram Singh Gill, military pharmacist with the Royal Medical and Dental Corps (RMDC) of the Malaysian Armed Forces (MAF),about his work at the Rohingya refugee camp in Cox's Bazar, Bangladesh.

Tapinarof proven safe, effective for psoriasis in phase II trial

11 Mar 2019
From the survey conducted, it is found that more than 80% of patients with psoriasis have experienced discrimination or humiliation across the world.

A phase II study has shown the efficacy and safety of tapinarof cream in adult patients with psoriasis.

The investigators assessed the safety and efficacy of tapinarof in a new cream formulation at two concentrations and with two application frequencies in this double-blind, vehicle-controlled, randomized, six-arm trial. Participants included adults with psoriasis with body surface involvement ≥1 percent and ≤15 percent and Physician Global Assessment (PGA) score ≥2 at baseline.

PGA of 0 or 1 at week 12 and a 2-grade improvement from baseline were the primary endpoints. Further analyses included assessment of ≥75-percent improvement of Psoriasis Area and Severity Index (PASI) and mean percent change in PASI and body surface area involvement.

Patients in the tapinarof groups had statistically significantly higher (at a 0.05 significance level) treatment success, defined by PGA 0 or 1 and a 2-grade improvement at week 12 (65 percent [1% twice daily], 56 percent [1% once daily], 46 percent [0.5% twice daily] and 36 percent [0.5% once daily]) than those in the vehicle groups (11 percent [twice daily] and 5 percent [once daily]).

Treatment success was maintained for 4 weeks post-treatment.

However, patients treated with tapinarof (85/152; 56 percent) were more likely to experience treatment-emergent adverse events (TEAEs) than those in the vehicle group (19/75; 25 percent). TEAEs were mild-to-moderate in intensity. Moreover, severe TEAEs were reported in all tapinarof groups except the 0.5% once-daily group.

Large confirmation trials are warranted, according to the investigators.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Rachel Soon, 03 Apr 2019

The Malaysian Community Pharmacy Guild (MCPG) has submitted a seven-point proposal for comprehensively including community pharmacists (CPs) in the national healthcare system.

14 May 2019
At the recent GLYCEMIC GUARDIANS™ dinner symposium, three eminent speakers spoke on theindispensable role of medical nutrition therapy (MNT) in improving outcomes for patients with type2 diabetes (T2D).
Rachel Soon, 24 Apr 2019

With recent recalls of losartan-containing products contaminated by potentially carcinogenic nitrosamines, MIMS speaks to the Malaysian National Pharmaceutical Regulatory Agency (NPRA) for more details.

Rachel Soon, 12 Dec 2018

MIMS Pharmacist speaks to Cpt. Manvikram Singh Gill, military pharmacist with the Royal Medical and Dental Corps (RMDC) of the Malaysian Armed Forces (MAF),about his work at the Rohingya refugee camp in Cox's Bazar, Bangladesh.